Exploring how ketamine affects the brain function in people with difficult-to-treat depression - NeuroKet 2.0

*This study is ongoing, date on last data collection expected 20/12/2027. Data will be available to request following publication of the primary outcome paper, for an indefinite time.

This dataset contains de identified clinical, behavioural, neuroimaging, and passive sensing data from an interventional randomised controlled study examining the neural and symptomatic effects of a single subcutaneous ketamine dose in adults with difficult to treat depression. Participants were randomised to receive ketamine (0.75 mg/kg) or saline placebo under medical supervision, with an additional healthy control group undergoing neuroimaging only. Ultra high field 7 Tesla functional MRI was conducted at baseline and 24-48 hours post intervention to assess habenula activity, connectivity, and photosensitivity, alongside clinician rated and self reported measures of depressive symptoms, anxiety, anhedonia, motivation, circadian preference, and quality of life. Objective behavioural and circadian measures were collected using actigraphy and passive mobile sensing before and after intervention. The dataset supports secondary analyses of ketamine's acute neural mechanisms, symptom change, and digitally derived behavioural markers in depression.